This web site was copied prior to January 20, 2005. It is now a Federal record managed by the National Archives and Records Administration. External links, forms, and search boxes may not function within this collection.
Chemotherapy regimens that include the drug docetaxel extend median survival by two to three months in patients with advanced prostate cancer that is no longer responsive to hormone therapy, according to two phase III clinical trials whose findings were presented at the 2004 ASCO meeting in New Orleans.
Adding the drug temozolomide (Temodar®) to radiation therapy for the treatment of a brain tumor called glioblastoma multiforme increased survival in a large randomized trial. While this approach has been customary in the United States for several years, these findings are definitive and should establish this approach as the standard of care.